What clinicians say about clinical trials, and why.
Source-linked reports for Medical Affairs on how clinicians read each trial, where their views differ, and which questions remain open. Weekly updates track what changes. Read them yourself, or query them from the AI tools your team already uses.
Explore the report previews
| Trial | Indication | Phase | Claims | HCP sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| PROUD-PV NCT01949805 · AOP Orphan Pharmaceuticals AG | Polycythemia vera | Phase 3 | 749 | 30 | Standard | 2026-10-08 | Preview |
| NEONIPIGA NCT04006262 · GERCOR - Multidisciplinary Oncology Cooperative Group | Gastroesophageal adenocarcinoma | Phase 2 | 1,222 | 60 | Deep | 2026-10-08 | Preview |
| CALGB-10403 NCT00558519 · Alliance for Clinical Trials in Oncology | Leukemia | Phase 2 | 1,065 | 28 | Standard | 2026-10-08 | Preview |
| MARS2 NCT02040272 · Royal Brompton & Harefield NHS Foundation Trust | Mesothelioma | Not applicable | 1,094 | 131 | Deep | 2026-10-08 | Preview |
| EURTAC NCT00446225 · Spanish Lung Cancer Group | Non-small cell lung cancer | Phase 3 | 210 | 9 | Focused | 2026-10-08 | Preview |
| SURTIME NCT01099423 · European Organisation for Research and Treatment of Cancer - EORTC | Renal cell carcinoma | Phase 3 | 427 | 32 | Standard | 2026-10-08 | Preview |
| MSLT-II NCT00297895 · Saint John's Cancer Institute | Melanoma | Not applicable | 499 | 36 | Standard | 2026-10-08 | Preview |
| EA3191 NCT04671667 · National Cancer Institute (NCI) | Head and neck squamous cell carcinoma | Phase 2 | 116 | 9 | Focused | 2026-10-07 | Preview |
8 of 8 reports
# What Erudio is and how to query it
curl https://www.erudio.com/llms.txt
# Every report, with counts, version and links
curl https://www.erudio.com/catalog.json
# One report as JSON or Markdown
curl https://www.erudio.com/reports/{slug}.json{
"mcpServers": {
"erudio": { "url": "https://mcp.erudio.com/mcp" }
}
}
# then ask your agent:
# search_reports({ "drug": "talazoparib" })- 8 reports
- weekly updates
- versioned editions
- every claim source-linked
Read one trial, or let your agent query them all.
One trial, one report
What clinicians said about a trial in podcasts, videos and posts, why their readings differ, and the source behind every view. Buy the current edition, or follow a trial with 3, 6 or 12 months of weekly updates.
Your agent, our evidence
Connect ChatGPT, Claude, Grok or your own agent to every report and to the underlying corpus of HCP podcasts, videos and posts, with no new app to learn. Ask “prep me for my meetings with these five oncologists” and get sourced answers.
Each report leads to the open question for Medical Affairs.
What evidence would make molecular response actionable after blood counts normalize?
Read the PROUD-PV preview →- HCP sources screened
- 33
- HCP sources screened
- verified claims
- 749
- verified claims
- people identity-verified
- 26
- people identity-verified
- findings
- 11
- findings
How a report is built
Every report separates what clinicians said from what the primary evidence establishes. We never turn commentary into an efficacy verdict or a consensus.
- 01
Resolve the trial
One registry record, its aliases, no look-alikes
- 02
Gather sources
Podcasts, videos and X posts that name the trial
- 03
Screen and extract
Each view, question and reason becomes a claim
- 04
Audit
Every claim checked against its original passage
- 05
Compose
What clinicians said and why, beside the primary facts
- 06
Review
Findings checked for fidelity and overclaiming
- 07
Version and publish
A hashed, versioned edition with a changelog
- Read the methods →
Built around the jobs Medical Affairs already does.
Meeting prep
Readout reaction
Congress briefing
Advisory boards
Competitive context
Evidence gaps
Launch and access signals
Trial watchlist
Education needs assessment
Public sources only. Every claim linked. Every edition versioned, with corrections in the open.
- Security-only SOC 2 Type II report, available under NDA
- Founded by the team behind Symplur, acquired by Real Chemistry in 2020
- Founders published on HCP conversation in BMJ, JAMA Oncology and the European Heart Journal
- Reports state what they do not cover, on every page
- Non-promotional: no efficacy verdicts, consensus scores or rankings. About Erudio